Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components

Clinical trial NCT05266404 · COMPLETED

Trial details

NCT number: NCT05266404
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)

Start date: 2022-03-21
Primary completion: 2022-05-31
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.